ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target
Tonglin Sun, Xi Li, Yi Zhang, Bingwen Zou, Yan Zhang · 2024
Read ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target by Tonglin Sun, Xi Li, Yi Zhang, Bingwen Zou, Yan Zhang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11671367.txt.
Description
Tonglin Sun and co-authors review a protein called ILF2 in a 2024 paper on its role in cancer. The protein helps control gene activity and partners with a related protein in many body tissues. Recent work finds far more of it in several tumor types than in healthy tissue.
High levels of the protein track with faster tumor growth, spread to new sites, new blood vessel growth, and worse outlook for patients. It also affects the cell cycle and a shift that helps cancer cells move. The review gathers these findings and weighs the protein as a marker for early diagnosis and outlook, and as a possible drug target. More proof is still needed before clinic use.
Catalog record
| CREATOR | Tonglin Sun, Xi Li, Yi Zhang, Bingwen Zou, Yan Zhang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |